Drugs / ASC30 tablets or ASC30 tablets A1 or placebo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07002905 | Jul → Dec 2025 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC30 tablets or ASC30 tablets A1 or placebo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07002905 ↗ |
| Route | Oral | “ASC30 tablets or ASC30 tablets A1 administered orally daily” NCT07002905 ↗ |